I followed the Japanese walking method for 30 days — here's what happened to my back pain and energy levels
As a fitness editor, I'm not one for health fads and trends, but when I tried the Japanese Interval Walking Training (IWT) method a month ago, I was immediately hooked.
The interval walking method originated in Japan, and is a form of HIIT training which promises to burn more fat than steady-paced walks and lower your blood pressure at the same time. A month later, I'm still doing it, and it's transformed my postnatal back pain and energy levels — read on to find out more.
What is the Japanese interval walking method?
As a refresher, here's what the walking workout entails:
Set a timer on your watch or phone and walk for three minutes at a low intensity. This should be a 4/10 effort — you're still moving, but you should easily be able to hold a conversation with someone next to you.
Then walk three minutes at a high intensity. This is a 7/10 walking effort — you should be working hard.
Keep switching between paces for 30 minutes.
What does the science say?
Studies have found IWT has several health benefits. After three months of doing a 30-minute interval walk three times a week, participants had a lower blood pressure and cholesterol, increased leg strength, and more aerobic capacity than those who walked continuously at a moderate pace for the same time.
You'll also burn more calories following the Japanese interval walking method than heading out for a steady 30-minute walk, as you'll increase your heart rate during those faster intervals. If you are walking to lose weight, it's a good idea to wear one of the best fitness trackers to see how many calories you're burning, as weight loss is the result of consuming less than you burn (often referred to as being in a calorie deficit).
I'm still following the Japanese interval walking method a month later — here's why
It's transformed my lower back
I'm 18 months postpartum, and while I'm physically able to do pretty much everything I could before having a baby, my lower back is still suffering. I had sciatica before my pregnancy, and the added weight of carting a toddler around on my hip means I'm experiencing a lot of stiffness in my lower back postpartum.
Walking is great for back pain, as it can reduce inflammation in the lower back and improve blood flow to the area. It can also increase the range of motion in the hips, which can help alleviate pain. If you are suffering from sciatica, always check with your doctor beforehand, and don't walk at a pace that feels uncomfortable on your back.
Walking workouts can also work on your core strength, which can, in turn, help support and stabilize your spine, reducing pain. Think about engaging your core when you walk, keeping your back straight, and sucking your belly button into your spine.
I've found that doing the Japanese interval walking method a few times a week has helped me break up long periods of sitting behind my desk with a walk, and as a result, I've not been anywhere near as stiff. Granted, some days the walk involves pushing my toddler in the running stroller and powering along, or keeping an eye on my unruly cocker spaniel, but it's become part of my routine, and one I enjoy.
It's boosted my energy levels
There's being tired, then there's being a mom. While I'm (thankfully) out of the days of newborn exhaustion, my baby still wakes at least once a night, so I'm still pretty far from the recommended nine hours of sleep. I've found that on days when I've averaged five hours of sleep, the Japanese interval method is much kinder on my body than heading out for a run, and I've even managed to complete the workout with a coffee in one hand (file that under mom multitasking).
There's science behind these mood-altering feelings — walking can increase blood flow around the body, combating fatigue. You'll also work hard for 30 minutes and receive a flood of endorphins, the body's natural mood-boosting chemicals, when you get back through the door.
What are you waiting for? Grab some sneakers and get walking.
Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.
More from Tom's Guide
I did the 12-3-30 treadmill workout for a month — here's my results
Forget running — 3 walking workouts that build lower body strength and burn calories
Forget 10,000 steps — I tried 'rucking' instead of regular walking for one week, and it's a game changer

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
38 minutes ago
- Medscape
Meta-Analysis Finds Biologic Switches Effective in Psoriasis
TOPLINE: Interclass biologic switching is effective and safe in patients with psoriasis, though switching from an anti-tumor necrosis factor (anti-TNF)-alpha to an anti-interleukin (IL)-17A treatment was associated with higher risk for adverse events (AEs), according to a meta-analysis. METHODOLOGY: To evaluate the safety and effectiveness of switching treatments after an initial biologic treatment fails, researchers conducted a meta-analysis of 24 randomized clinical trials published through January 25, 2025, which included 12,661 adults with psoriasis who switched from one biologic agent to another within the same class or in a different class. Eight switching categories were analyzed. The primary endpoint was the Psoriasis Area and Severity Index (PASI) 90 score, and secondary endpoints included safety. TAKEAWAY: PASI 90 improved significantly in patients after interclass biologic switching both at week 4 (11 studies; odds ratio [OR], 6.53; 95% CI, 2.58-16.51) and long term (OR, 28.61; 95% CI, 12.89-63.47). All switches were effective in the short term, whereas most switches achieved a PASI 90 response in the long term, except for switches from anti-IL-17A agents to anti-IL-17A/F agents. Long-term, marked improvements were observed when switching from anti-TNF-alpha agents to anti-IL-23p19 agents (OR, 23.72; 95% CI, 4.29-130.98) and from anti-IL-12/23p40 agents to anti-IL-23p19 agents (OR, 19.87; 95% CI, 10.40-37.94). No major safety differences were observed overall, except for increased serious adverse events (AEs) when switching from an anti-TNF-alpha agent to an anti-IL-17A agent (OR, 2.45; 95% CI, 1.25-4.83). Switching from anti-TNF-alpha agents to anti-IL-23p19, anti-IL-17A, or anti-IL-12/23p40 agents was associated with infection rates of 0.62%, 0.54%, and 0.39%, respectively. The highest risk for Candida infection (0.16%) was observed when switching from anti-TNF-alpha agents to anti-IL-17A/F agents. Switching to a different biologic class showed comparable effectiveness and safety with continuing the same agent, with regards to AEs. IN PRACTICE: This systematic review and meta-analysis found that 'interclass biologic switching was effective, and there were no safety differences for most patients,' the study authors wrote. 'Switching to anti-IL-23p19, anti-IL-17A, or anti-IL-12/23p40 agents from anti-TNF-alpha agents posed the greatest risk of infection,' they added, recommending 'vigilance for infections while switching to different biologics.' SOURCE: The study was led by Miao Zhang, MD, Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China, and was published online on August 6 in JAMA Dermatology. LIMITATIONS: Limitations included heterogeneity in study designs, potential differences between biologics and batch variability which could have affected effectiveness comparisons after switching, insufficient data for several comparisons. DISCLOSURES: The study was supported by the National Natural Science Foundation of China, the Key Discipline Construction Project of Shanghai's 3-Year Action Plan for Strengthening the Construction of Public Health System, Shanghai Oriental Talent Program for Top-notch Project, CACMS Innovation Fund, Shanghai Healthy Special Project, The Shanghai 2022 Science and Technology Innovation Action Plan Medical Innovation Research Special Project, the Clinical Research Plan of Shanghai Shenkang Hospital Development Center, the High-level Chinese Medicine Key Discipline Construction Project, Evidence-based dermatology base sponsored by State Administration of Traditional Chinese Medicine, and the Shanghai Hospital Development Center Foundation. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
Private clinics accuse health minister of ‘complicity or absence' in face of NACCOL ‘overreach'
KUALA LUMPUR, Aug 7 — The Federation of Private Medical Practitioners' Associations, Malaysia (FPMPAM) has accused the health minister of failing to defend doctors against policy overreach by the National Action Council on Cost of Living (NACCOL). FPMPAM president Dr Shanmuganathan Ganeson criticised Datuk Seri Dzulkefly Ahmad for keeping silent when the deputy minister of domestic trade and cost of living cited NACCOL's 'mandate' in Parliament to justify new rules for private clinics. 'These were policy suggestions, not legally binding directives, but the way they were presented has caused widespread confusion,' Dr Shanmuganathan said in a statement. He said the minister's failure to speak up during NACCOL meetings showed either 'complicity or absence' in protecting the medical profession. 'The full responsibility — and the failure — lies with the minister of health himself,' he said. FPMPAM also criticised the government for pushing mandatory drug price displays and prescriptions without proper legal authority or consultation. Dr Shanmuganathan said clinical decisions such as issuing prescriptions or itemised billing fall under the Ministry of Health and Malaysian Medical Council (MMC), not NACCOL. He argued that forced itemised billing could increase healthcare costs for patients. 'We are not NACCOL's subjects. We are the custodians of patient care,' he said. The association then demanded that the minister publicly state his position and take steps to restore trust among private medical professionals.


Entrepreneur
an hour ago
- Entrepreneur
Thyrocare CEO Rahul Guha to Lead PharmEasy as Siddharth Shah Steps Down
Effective August 27, 2025, Shah will assume the position of Vice Chairman and Director at the parent company of PharmEasy and Thyrocare. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Siddharth Shah, Co-founder and current MD and CEO of API Holdings, is stepping down from his executive role later this month. Effective August 27, 2025, Shah will assume the position of Vice Chairman and Director at the parent company of PharmEasy and Thyrocare. Rahul Guha, presently the MD and CEO of Thyrocare, has been appointed as the new MD and CEO of API Holdings. The leadership change was disclosed in regulatory filings by Thyrocare on Wednesday. Guha will continue to oversee Thyrocare while taking on his new responsibilities at API Holdings. Guha brings significant experience to the role. Prior to his elevation, he served as President of Operations at API Holdings, where he led group-level integration and coordination efforts. PharmEasy had acquired a controlling 66.1 percent stake in Thyrocare in June 2021 for INR 4,546 crore. The leadership consolidation is seen as a strategic step by API Holdings to streamline operations amid ongoing financial challenges and long-term preparations for a potential public listing. API Holdings had earlier filed draft documents for an initial public offering in 2021 but withdrew due to unfavorable market conditions. The company has raised approximately USD 1.1 billion from investors such as MEMG, Prosus, and Temasek. In April 2024, it secured USD 216 million in funding at a significantly reduced valuation of USD 710 million. The transition follows the departure of PharmEasy's three cofounders earlier this year. The trio has since launched a new startup, All Home, which recently raised funding from Bessemer Venture Partners, valuing it at over USD 120 million. Shah has also invested in the venture.